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Timolol maleate (TiM), a nonselective b-adrenergic blocker, is a potent highly effective agent
for management of hypertension. The drug suffers from extensive ﬁrst pass effect, resulting
in a reduction of oral bioavailability (F%) to 50% and a short elimination half-life of 4 h;
parameters necessitating its frequent administration. The current study was therefore, designed
692 N.M. Morsi et al.Accepted 6 July 2016
Available online 15 July 2016
Keywords:
Antihypertensive
Transfersomes
Transdermal
Timolol maleate
Factorial design
Optimizationto formulate and optimize the transfersomal TiM gel for transdermal delivery. TiM loaded
transfersomal gel was optimized using two 23 full factorial designs; where the effects of egg
phosphatidyl choline (PC): surfactant (SAA) molar ratio, solvent volumetric ratio, and the drug
amount were evaluated. The formulation variables; including particle size, drug entrapment efﬁ-
ciency (%EE), and release rate were characterized. The optimized transfersomal gel was pre-
pared with 4.65:1 PC:SAA molar ratio, 3:1 solvent volumetric ratio, and 13 mg drug amount
with particle size of 2.722 lm, %EE of 39.96%, and a release rate of 134.49 lg/cm2/h. The per-
meation rate of the optimized formulation through the rat skin was excellent (151.53 lg/cm2/h)
and showed four times increase in relative bioavailability with prolonged plasma proﬁle up to
72 h compared with oral aqueous solution. In conclusion, a potential transfersomal transdermal
system was successfully developed and the factorial design was found to be a smart tool, when
optimized.
 2016 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Timolol maleate is a b-adrenergic blocking agent that exhibits
an anti-hypertensive activity, protects against angina pectoris,
and myocardial infarction. Due to its short elimination half-
life (4 h), it is orally administered twice daily. Additionally;
because of poor bioavailability (50%), a high oral dose of
10–60 mg/day was required. As an adverse effect, bron-
chospasm was reported in some patients [1].
Transdermal delivery represents an attractive solution to
oral problems. It bypasses the liver ﬁrst pass effect; hence
the bioavailability is expected to be increased. Additionally,
it can be simply terminated and removed from the skin, if
any of the side effects show up. Furthermore, the use of the
vesicular system in the transdermal drug delivery may sustain
the release of the drug, thus lowers its frequency of administra-
tion [2]. Despite the many advantages of the skin as a site of
drug delivery, only few drugs are currently available in the
market as transdermal delivery systems. This is because the
inherent limitation of transdermal drug absorption, which is
imposed by the outermost layer of the skin, the stratum cor-
neum (SC) [3]. From 1991, several researches were focused
on transfersomes in transdermal drug delivery system to over-
come this intrinsic barrier. Transfersomes can penetrate efﬁ-
ciently various transport barriers, even through the pores or
constrictions that would be conﬁning for other particulates
of comparable size. This capability is due to the self-
adaptable and extremely high deformability of the transfer-
somes’ membrane [4]. In contrast to other methods permeating
the skin; transfersomes create drug depots in the skin that can
slowly and gradually deliver the material under the skin and/or
the systemic circulation without invasion [5]. Transfersomes
are complex aggregate, composed of phospholipids, surfac-
tant, and water; prepared by thin ﬁlm hydration or modiﬁed
hand shaking, lipid ﬁlm hydration technique [5].
Analysis and understanding the appropriate combination
of independent process and/or formulation variables (factors),
which produce the optimized product can be established by
statistical design of experiment tools, such as factorial designs.
It is considered as the most effective way in estimating the
inﬂuence of individual process variables with minimum exper-
imentation and time, where all factors are tested in all possible
combinations [6]. The aim of the present study was therefore,
to develop timolol maleate transfersomal gel formulation bythin ﬁlm hydration method for transdermal uses. Two 23 full
factorial designs were employed to optimize and explore the
effect of three formulation variables; including phosphatidyl-
choline: surfactant molar ratio, the solvent volumetric ratio,
and the drug amount using two different surfactants (Tween
80 and Span 80). The aforementioned effects were evaluated
on each of the particle size of the vesicles, the percentage
entrapment efﬁciency of the drug, and the release rate through
synthetic membrane. The optimized formulation was subjected
to permeation studies using shaved rat skin and in vivo phar-
macokinetics studies were carried out on Wistar rats on the
optimized formulation; comparing the results with the oral
solution.Material and methods
Materials
Timolol maleate (TiM) was a gift from Sedico Company
(Giza, Egypt). L-a-phosphatidylcholine (PC) (type IV-S) and
Span 80 (S80) were purchased from Sigma Aldrich (St. Louis,
MO, USA). Tween 80 (T80) was obtained from Scharlau Che-
mie (Sentmenat, Spain). Carbopol 934 was supplied by
Lubrizol Corporation (Ohio, USA). Naproxen sodium powder
was a generous offer from El-Nile Pharmaceutical Chemical
Company (Cairo, Egypt). All other chemicals and solvents
were of pharmaceutical grade.
Preparation of transfersomes
Transfersomes were prepared by dry thin ﬁlm hydration
method [7]. A mixture of PC and surfactant (SAA) with differ-
ent ratios was dissolved in 12 mL mixture of chloroform and
methanol to form 5% w/v solution. The solvent was removed
by rotary evaporation at 55 C under reduced pressure (Hei-
dolph 2, Schwabach, Germany) till a thin ﬁlm is produced.
The ﬁlm was hydrated with 10 mL of phosphate buffer saline
(PBS) pH 7.4, containing the drug. The formed suspension
was subsequently sonicated for 10 min using bath type sonica-
tor at 900H at temperature 25 C (Jiotech UC-10, Serangoon,
Singapore). The suspension was left overnight for maturation
of vesicles and kept under vacuum to ensure the removal of
residual solvent.
Evaluation and optimization of timolol maleate transfersomal gel 693Experimental design
Two 23 full factorial designs were employed using Design-
Expert 7.0.0 software (Stat-Ease Inc., USA), one using T80
and the other using S80 as the SAA. In these designs, three
independent formulation variables were studied to evaluate
their individual and combined effects; PC:SAA molar ratio
(XA), chloroform: methanol volumetric ratio (XB), and amount
of drug added (XC), each at two levels. The experimental trials
were performed at all eight possible combinations with 3 times
replication for each transfersomal system. The effect of particle
size (P.S.), percentage entrapment efﬁciency (%EE), and the
timolol maleate (TiM) release rate through synthetic mem-
brane on transfersomes performance and characteristics were
tested and optimized. The levels of the independent variables
were chosen based on the preliminary experiments (results
not shown). The full factorial designs including investigated
independent and dependent variables are shown in Table 1.
The one-way analysis of variance (ANOVA) was applied to
estimate the signiﬁcance of the model (P< 0.05) and individ-
ual response parameters.
Morphology and vesicle size measurement
The mean vesicle size and morphology of the prepared trans-
fersomes were determined using the optical microscope (Leica
Imaging Systems, Cambridge, UK) with a digital camera
(JVC, Victor Co, Yokohama, Japan) [8]. A thin layer of trans-
fersomal formulation was spread on a slide and examined after
placing the cover slip. The average size of at least 100 particles
was measured.
Determination of entrapment efficiency of TiM in transfersomes
One mL of the previously prepared suspension was centrifuged
at 18,000g for 1 h at a temperature of 4 C using cooling cen-
trifuge (Megafuge 16R, Hanau, Germany), followed by
washing the precipitate twice with PBS at pH 7.4 [9–11]. The
free TiM concentration (Cf) in the resulting supernatant and
the resulting washing solution was assayed spectrophotometri-
cally at 294 nm after ﬁltration and suitable dilution. The %EE
of the drug was calculated from the following equation as
follows:
%EE ¼ ½ðCt  CfÞ=Ct  100Table 1 Variables in factorial design.
Levels used
1 1
Independent variables
XA: PC:SAA molar ratio 3:1 9:1
XB: CHCl3:CH3OH volumetric ratio 1:1 3:1
XC: Drug amount 7 mg 13 mg
Dependant variables
Y1: Particle size (lm)
Y2: Percentage entrapment eﬃciency
Y3: Release rate (lg/cm
2/h)where Ct is the total added theoretical concentration of TiM
used in the preparation of transfersomes and Cf is the concen-
tration of unentrapped TiM [12].
Preparation of transfersomal gel
Transfersomal gel was prepared by adding 0.5 g Carbopol
portion wise by sprinkling to 4 mL of the previously prepared
suspension and stirring 8-wise direction until a gel was formed.
In vitro release study
In vitro release studies were carried out using vertical diffusion
Franz cells (Hanson Research Corp, CA, USA) with an effec-
tive diffusion area of 1 cm2. The receptor’s compartment vol-
ume was 7 mL (PBS, pH7.4), maintained at 37 C± 0.5 and
stirred by a magnetic bar at 500 g. The donor compartment
was separated from the receptor compartment by cellophane
membrane (cut-off 12,000–14,000) (Spectrum Medical Inc.,
Los Angeles, CA, USA). Sample (1 g) of the gel was placed
in the donor compartment. Four hundred lL aliquots were
withdrawn from the sampling port at 0.5, 1, 2, 3, 4, 5, 6, 8,
12, 18 and 24 h and substituted with fresh buffer, to maintain
a constant volume and then analyzed spectrophotometrically
at 294 nm. The calculated TiM concentration was plotted as
a function of time. The rate of drug release was calculated
from the slope of the initial portion of the graph [12–14].
In vitro rat skin permeation study
In vitro permeation study was conducted on the optimized for-
mulations from the two factorial designs using vertical type
diffusion cell as described above. However, instead of synthetic
cellophane membrane a shaved rat skin was used [13]. The per-
meation study was applied under non-occlusive conditions.
Samples were collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6,
12, 18, and 24 h of time interval, for the two optimized formu-
lations. The calculated TiM concentration was plotted as a
function of time (h) for each formulation.
In vivo pharmacokinetics study
Study protocol
In vivo studies were performed on male Wistar Albino rats to
compare the absorption of transdermal gel with oral absorp-
tion of TiM aqueous solution. Rats were housed in animal
facilities under standard laboratory conditions prior to exper-
imentation. All investigations were performed after approval by
the MSA University ethical committee (Ethical committee
approval No. AE/22/H8). Twenty rats (weighing from 200 to
250 g) were used and divided into two groups; 10 rats each.
The hair on the abdominal side of one group was cut off using
scissors and the gel was spread over the back non-occlusively.
The other group was given TiM aqueous solution orally using
a plastic syringe. Gel and oral solution equivalent to 5 mg TiM
were given to both groups. The skin was measured for the pres-
ence erythema and edema according to the following scaling
system; the erythema scale was as follows: 0, none; 1, slight;
2, well deﬁned; 3, moderate, and 4, scar formation, whereas
the edema scale was: 0, none; 1, slight; 2, well deﬁned; 3,
Fig. 1 Light photos for the optimized transfersomal formulae (a) using T80 and (b) using S80 as the surfactant.
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scores was rated as follows: 0, none; 1–2 mild; 3–5, moderate;
and 6–8, severe irritation [15].
To measure the concentrations of TiM, blood samples
(500 lL) were obtained from the retinovascular plexus of the
eye using heparinized capillaries. Samples were centrifuged at
4000g for 10 min to obtain plasma, which stored at 20 C
in labeled tubes pending HPLC analysis.
HPLC assay
The quantitative determination of drug was performed by a
validated HPLC method [16], using acetonitrile: 0.2% triethy-
lamine (60:40, v/v) (pH 2.75 adjusted with 85% phosphoric
acid) as a mobile phase delivered at 1.0 mL/min. The HPLC
system equipped with degasser (G1379A), quaternary pump
(G1311A), auto-sampler with 50 lL injection loop, column
thermostat (G1316A) and UV detector (G1315C). The column
oven temperature was kept at 45 C and the peak response was
monitored at a wavelength of 294 nm. The mobile phase sys-
tem control and data acquisition were made with the Agilent
Chem Station Version A 10.02 (Agilent Technologies, Munich,
Germany). Standard addition technique was adopted so as to
detect the small quantities of the drug in the samples [16,17].Table 2 23 full factorial design layout.
Formula code Independent variable levels in coded form
XA XB XC
1T 1 1 1
2T 1 1 1
3T 1 1 1
4T 1 1 1
5T 1 1 1
6T 1 1 1
7T 1 1 1
8T 1 1 1
1S 1 1 1
2S 1 1 1
3S 1 1 1
4S 1 1 1
5S 1 1 1
6S 1 1 1
7S 1 1 1
8S 1 1 1Pharmacokinetics and statistical analysis
Pharmacokinetics parameters were calculated using the plasma
concentration vs. time, using non-compartmental analysis
(Kinetica 5, Thermo Fisher Scientiﬁc, Waltham, Mas-
sachusetts, USA).
Results and discussion
Preparation of transfersomes
Based on preliminary experiments, transfersomes were pre-
pared by thin ﬁlm hydration method rather than reverse phase
evaporation (REV), because it produces multilamellar vesicles
(MLV) with higher drug loading [9].
Morphology
Fig. 1 represents the photomicrographs of the optimized for-
mulations using T80 and S80. It shows the outline and core
of the well-identiﬁed spherical shaped vesicles, displaying theSAA Dependant variables
Y1 ± S.D. (lm) Y2 ± S.D. Y3 (lg/cm
2/h)
T80 1.61 ± 0.042 49.9 ± 0.459 197.33
1.73 ± 0.042 11.6 ± 0.325 130.29
2.74 ± 0.084 69.2 ± 1.209 186.89
1.45 ± 0.353 32.73 ± 0.855 168.13
1.5 ± 0.141 37.68 ± 0.318 166.42
2.42 ± 0.042 33.85 ± 0.77 113.38
3.645 ± 0.403 7512 ± 2.715 46.26
3.205 ± 0.106 85.2 ± 0.728 125.4
S80 1.925 ± 0.1 47.5 ± 0.721 46.274
3.85±.07 11.67 ± 1.918 33.257
3.5 ± 0.14 60.559 ± 0.607 30.673
2.985 ± 0.035 29.7 ± 1.007 60.28
3.36 ± 0.127 25.94 ± 1.018 82.458
3.2 ± 0.48 26.98 ± 0.084 176.32
1.72 ± 0.113 67.2 ± 1.343 31.556
2.655 ± 0.289 50.1 ± 2.186 69.682
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homogenous in shape.
Experimental design
Based on the factorial design of experiment, the optimization
technique encompassed the generation of model equations
for the investigated dependent variables over the experimental
design, to determine the optimum formulation(s). Coefﬁcients
with one factor represent the effect of that particular factor
while the coefﬁcients with more than one factor represent the
interaction between those factors. The polynomial equations
can be used to draw conclusions after considering the magni-
tude of coefﬁcient and the mathematical sign it carries. A pos-
itive sign in front of the terms indicates synergistic effect, while
negative sign indicates antagonistic effect of the factors. The
results of dependent variables were represented in Table 2.
Table 3 shows the one-way ANOVA, which estimates the sig-
niﬁcance of the model (P< 0.05) and individual response
parameters [18].
Vesicle size
The mean vesicle size using T80 was ranged from 1.45 to
3.64 lm, whereas that of S80 ranged between 1.72 and
3.85 lm (Table 2). Eqs. (1) and (2) represent the linear
regression models for particle size (P.S.) using T80 and S80
transfersomes, respectively, as obtained from factorial design
study.Table 3 Sum of squares, degree of freedom, mean squares, F-valu
Factorial Study for the measured dependent variables using T80 and
Term Sum of squares d.f. Mean squares F value P valu
Particle size
XA T80 0.89 1 0.89 12.14 0.0069
XB 9.025 1 9.025 0.12 0.7342
XC 1.33 1 1.33 18.14 0.0021
XAB 3.57 1 3.57 48.57 <0.00
XAC 0.86 1 0.86 11.76 0.0075
XBC 2.99 1 2.99 40.69 0.0001
XABC 0.33 1 0.33 7.98 0.0523
%EE
XA T80 4.01 1 4.01 0.74 0.4105
XB 1899.09 1 1899.09 353.11 <0.00
XC 269.67 1 269.67 50.14 <0.00
XAB 4184.60 1 4184.60 778.08 <0.00
XAC 209.05 1 209.05 38.87 0.0002
XBC 2151.24 1 2151.24 400.00 <0.00
XABC 31.57 1 31.57 15.00 0.547
Release rate
XA T80 43.86 1 43.86 2.04 0.1867
XB 10903.01 1 10903.01 507.98 <0.00
XC 2740.26 1 2740.26 127.67 <0.00
XAB 1864.30 1 1864.30 86.86 <0.00
XAC 11926.28 1 11926.28 555.66 <0.00
XBC 7277.37 1 7277.37 339.06 <0.00
XABC 45.39 1 45.39 2.46 0.1556Particle size using T80 ¼ 2:29 0:24XA þ 0:024XB
þ 0:29XC þ 0:47XAB
þ 0:23XAC þ 0:43XBCÞ ð1Þ
[where F= 21.9, P< 0.0001 and R2 = 0.93]
Particle size using S80 ¼ 2:9 0:4XA þ 0:039XB
þ 0:46XC  0:18XAB  3:12XAC
 0:52XBC ð2Þ
[where F= 15.28, P< 0.0001 and R2 = 0.91]
The P.S was reduced by increasing the PC: SAA molar ratio
as can be deduced from the negative coefﬁcient of XA. This
might be attributed to the decreases in the SAA, which lead
to incomplete maturation of vesicles and thus reduction in
their sizes [8]. On the other hand, with increase in the drug
amount, the particle size was increased, which may be due to
the increases in drug loading [19]. As can be deduced, using
different surfactants did not have a signiﬁcant difference on
the particle size being prepared by the same method. This
ﬁnding was in accordance with that reported by Song and
Kim [11].
Entrapment efficiency
Entrapment efﬁciency is the percent of the total drug incorpo-
rated into the transfersomes [13]. Eqs. (3) and (4) represent the
linear regression models for %EE using T80 and S80 transfer-
somes, respectively, as obtained from factorial design study.es and P-values for the Model Coefﬁcients Estimated from the
S80.
e Sum of squares d.f. Mean squares F value P value
S80 2.58 1 2.58 31.23 0.0003
0.025 1 0.025 0.30 0.5973
0.033 1 0.033 0.40 0.5416
01 0.54 1 0.54 6.57 0.0305
1.562E004 1 1.562E004 1.888E003 0.9663
4.40 1 4.40 53.17 <0.0001
0.36 1 0.36 7.61 0.5247
S80 123.52 1 123.52 1.54 0.2464
01 576.95 1 576.95 7.18 0.0252
01 479.42 1 479.42 5.97 0.0372
01 2334.17 1 2334.17 29.05 0.0004
9.47 1 9.47 0.12 0.7392
01 1012.91 1 1012.1 12.61 0.0062
700.78 1 700.78 251.19 0.2341
S80 1809.95 1 1809.9 294.20 <0.0001
01 1276.60 1 1276.6 207.51 <0.0001
01 3185.53 1 3185.5 517.80 <0.0001
01 4907.28 1 4907.2 797.67 <0.0001
01 2417.49 1 2417.4 392.96 <0.0001
01 3017.20 1 3017.2 490.44 <0.0001
14265.08 1 14265.08 2318.76 <0.0001
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Fig. 2 (a) In vitro release proﬁles of TiM from transfersomes
from formulae (1T–8T) using T80. (b) In vitro release proﬁles of
TiM from transfersomes from formulae (1S–8S) using S80.
696 N.M. Morsi et al.%EE for T80 ¼ 49:3 0:5XA  10:89XB þ 4:11XC
þ 16:17XAB þ 3:61XAC þ 11:6XBC ð3Þ
[where F= 270.16, P< 0.0001 and R2 = 0.9945]
%EE for S80 ¼ 38:93þ 2:7XA  6XB þ 5:476XC
þ 12:08XAB  0:77XAC þ 7:96XBC ð4Þ
[where F= 9.41, P< 0.0001 and R2 = 0.86]
The negative coefﬁcient of XB reveals the increases in the
chloroform: methanol volumetric ratio, which leads to a
decrease in the %EE. While an increase in the %EE was
observed with the increase in the drug amount could be attrib-
uted to drug enforcement to encapsulated vesicles [12]. As can
be observed, from the positive coefﬁcient of the interaction
between any of XAB, XAC and XBC, the %EE is synergistically
increased by any interaction.
Formulations using T80 had higher %EE than S80 as
shown from the coefﬁcients of Eqs. (3) and (4), which could
be attributed to the higher phase transition temperature pos-
sessed by T80 [10] that yield a higher %EE [8].
In vitro release
Fig. 2 represents the in vitro release proﬁle of the drug from the
formulations which followed a biphasic release. This could be
attributed to the presence of free drug together with the
entrapped one, which is due to the limited capacity of the lipid
to accommodate large amounts of the drug leading to disposi-
tion of the free drug at the surface. This in turn lead to an ini-
tial rapid release (due to the presence of the free drug and the
drug adsorbed on the surface), followed by slower sustained
release phase due to diffusion of the entrapped drug through
the lipid bilayers of the vesicles, which is very effective in sus-
taining and controlling the release of TiM. These ﬁndings were
in accordance with El Zaafarany et al. [9].
Eqs. (5) and (6) represent the linear regression models for
the release rate through synthetic membrane using T80 and
S80 transfersomes respectively, as obtained from factorial
design study.
Release rate using T80 ¼ 140:93þ 1:66XA  26:1XB
 13:09XC  10:79XAB
 27:3XAC  21:33XBC ð5Þ
[where F= 269.88, P< 0.0001, R2 = .9984]
Release rate using S80 ¼ 65:79 10:64XA þ 8:93XB
þ 14:11XC  17:51XAB
 12:29XAC þ 13:73XBC ð6Þ
[where F= 269.88, P< 0.0001, R2 = 0.9984]
It is well reported that any factor that increases the
formation of the transfersomes or increases its %EE, affects
the release rate, as the drug passes through the bilayers of
the vesicular structure leading to a decrease in the release rate
[20].
When S80 was used as the SAA, the release rate was found
to be delayed by increasing the PC:SAA molar ratio. This maybe due to the increase in the transfersomes yield due to the
increase in the body of transfersomes by increasing the PC
amount, which hinder the release of the entrapped drug as well
as the free one [21].
The release rate was augmented as the solvent volumetric
ratio increased while using T80 and was hindered while using
S80. The difference in the behavior could be attributed to
the variation in hydrophilic/lipophilic balance between T80
and S80 that lead to dissimilarity in their solubility which
ﬁnally lead to the difference in the release rate.
Also the release rate was found to be reduced by increasing
the amount of the drug added when T80 was used which may
be due to the increase in the %EE, while when S80 was used;
the release rate was found to be accelerated.
It is worth to note that all studied independent variable
(factors) and their binary interactions were signiﬁcant for all
studied dependent variables (responses) with some exceptions;
where when T80 was the used SAA, the effect of XA was
insigniﬁcant on both the %EE and the release rate and the
effect of XB was insigniﬁcant on the particle size.
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Evaluation and optimization of timolol maleate transfersomal gel 697While using S80; the interaction of XAC was insigniﬁcant on
the particle size and the %EE, and the effect of XA was
insigniﬁcant on the %EE and ﬁnally the XB and XC had
insigniﬁcant effects on the particle size. This may reﬂect the
good choice for the studied variables.
3D surface plots
3-D surface plots were obtained by ﬁxing the XC factor at its
high and low level and varying (XA) and (XB) over the range
used in the factorial study. Fig. 3 depicts 3-D plots which show
the effects of XA and XB on P.S., %EE and the release rate.
Optimization
A numerical optimization technique using the desirability
approach was employed to develop new optimized formula-tions with desired response. The optimal values of responses
were obtained by numerical analysis using the Design-Expert
7.0.0. software. Our constraints were the smallest particle size,
highest %EE and the slowest release rate. The optimized for-
mulation using T80 contained 8.7:1 PC:SAA molar ratio, 1:1
solvent volumetric ratio and 7 mg drug amount, with
desirability 0.8, while using S80 4.65:1 PC:SAA molar ratio,
3:1 solvent volumetric ratio and 13 mg drug amount, with
desirability 0.595.
A new batch was prepared and evaluated from the software
at determined levels. Results depicted in Fig. 4 show the release
rate of the optimized formulations. The results of expected and
observed values for the optimized transfersomal formulations
are shown in Table 4. The observed results of independent
variables were very close to the expected values as shown from
the small residual values. This proves the validation of our
models.
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Fig. 3b 3D of %EE, (a) and (b) using T80, (c) and (d) for using S80 (a) and (c) for low level of XC and (b) & (d) for high level of XC.
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The conditions were conducted non-occlusively as recom-
mended by other [22]. This may be due to the presence of
the non-chemical gradient, the hydration gradient, which is
created by the difference in the total water content between
the skin surface and the interior of the skin. When the transfer-
somal formulation was placed on the skin, it is partly dehy-
drated by the water evaporation loss which creates the
hydration gradient, which in turn enforces the transfersomes
to enter to the skin to avoid complete hydration. This gradient
can only be achieved when the formulation is applied under
non-occlusive conditions to allow the water loss from the sur-
face of the skin to create the driving force for permeation. This
movement can be achieved easily due to the high ﬂexibility of
the transfersomes [22]. Another mechanism is that the transfer-
somes can act as a penetration enhancer, as suggested by El
Zaafarany et al. [9]. This action is achieved as the vesicles
bilayers enter the SC and modify the intercellular lipids, whichraise its ﬂuidity and weakness and thus can overcome the bar-
rier property of the skin. So these ﬁndings indicate that both
the entrapped and the free drugs are carried through the SC
and deep to different layers of the skin.
The permeation rate was less than the release rate, which
gives an indication of the depot action of the viable skin layers,
allowing the release to be more sustainable [14].
It could be inferred from Fig. 5 that S80 had better perme-
ation than T80. This ﬁnding was in line with Jain et al. [14],
who attributed the reason to the higher afﬁnity with the lipid
bilayer.
In-vivo pharmacokinetics study
Skin irritation study
After the removal of the dosage form, no signs of erythema or
edema (all had 0 scales) were observed at the application sites.
This means that the preparations were well tolerated by the
skin throughout the whole tested period.
Table 4 The observed and the predicted values for the
optimized transfersomal formulations.
Dependent variable Expected Observed Residuala
(a) Using T80
P.S. (lm) 1.46 1.26 0.2
%EE 48.0175 43.678 4.3395
Release rate (lg/cm2/h) 198.55 166.51 32.04
(b) Using S80
P.S.(lm) 2.722 2.4 0.322
%EE 39.96 33.19 6.77
Release rate (lg/cm2/h) 134.49 151.53 17.04
a Residual = expected-observed.
a b
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Fig. 3c 3D of release rate, (a) and (b) using T80, (c) and (d) for using S80 (a) and (c) for low level of XC and (b) & (d) for high level of XC.
-200
0 
200
400
600
800
1000
1200
1400
1600
1800
0 5 10 15 20 25 30
Q
cu
m
 (µ
g/
m
L/
cm
2 )
 
Time (h)
Tween 80
Span 80
Fig. 4 In vitro release proﬁle of TiM from optimized
formulations.
Evaluation and optimization of timolol maleate transfersomal gel 699Pharmacokinetics and statistical analysis
Plasma proﬁle of TiM from transfersomal gel through rat skin
and absorption from single oral dose administration is shown
in Fig. 6 and Table 5. After oral administration, the peak
plasma concentration, Cmax, was 29.9 ng/mL and the tmaxwas 1.5 h. With transdermal gel, prolonged plasma concentra-
tion for over 72 h was observed as indicated by decreased Cmax
(10.53 ng/mL) and delayed Tmax (24 h). The mean AUC0 to 24
and AUC0 to 1 of the optimized TiM gel were increased 4.45
and 3.39 folds compared to TiM oral solution, respectively.
This increase in the bioavailability could be due to bypassing
Table 5 Mean pharmacokinetic parameters of TiM oral
solution and optimized transfersomal gel.
Pharmacokinetics
parameter
TiM oral
solution
TiM transfersomal gel
Cmax
* (ng/ml) 29.90 10.53
Tmax
* (h) 1.50 24
AUC0 to 24
* (ng/lL  h) 0.142251 0.633585
AUC0 to 1
* (ng/lL  h) 0.136219 0.462407
* Signiﬁcant at P< 0.1.
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700 N.M. Morsi et al.the ﬁrst pass effect with transdermal preparation. The pro-
longed plasma proﬁle and improved bioavailability of TiM
from the optimized formulation could suggest the reduction
of both frequency of administration and dose that would lead
to good patient compliance, lower cost, and reduction of the
dose related side effects.
Conclusions
Transdermal transfersomal formulation of TiM can be consid-
ered as a golden solution, which overcomes most of the oral
problems. It sustained the release of the drug up to 72 h and
increased the relative bioavailability in comparison with oralroute. Additionally, factorial design was found to be a smart
tool in its optimization. Finally, transdermal transfersomal
timolol maleate gel could be a potential candidate for the treat-
ment of hypertension.
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